EGFR and colorectal cancer: Although anti-EGFR antibodies are likely to be used in the first-line treatment of RAS wild-type, left-sided colorectal cancer, no conclusion has been reached as to whether the primary site influences the effect of anti-EGFR antibodies in previously treated patients.